India secures US tariff exemption on specialty drugs amid Trump's 100% pharma levy threat
India has secured an exemption from US tariffs on specialty drugs, even as the Trump administration prepares to impose a 100% levy on the broader pharmaceutical sector.
The development comes as the US signals a shift in trade policy toward higher tariffs. India's pharmaceutical exports, a major economic contributor, have faced uncertainty amid these tariff discussions.
The exemption on specialty drugs offers some relief to Indian pharma manufacturers, though the broader sector remains vulnerable to the proposed comprehensive tariff regime.
